UBQLN2 in neurodegenerative disease: mechanistic insights and emerging therapeutic potential
Biochemical Society Transactions · 2025
DOI: 10.1042/bst20253053 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, 2025. Verfasst von Autumn M Matthews und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Colorado Boulder, Boulder, Colorado, 80309, U.S.A. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Neurodegenerative Diseases, Cell Cycle Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Ubiquilins (UBQLNs) regulate cellular protein turnover by shuttling proteins, or ‘clients’, to the proteasome or autophagy pathways for degradation. Of the five different UBQLN genes in humans, UBQLN2 is the most highly expressed in the nervous system and muscle tissue and has been linked to multiple neurodegenerative diseases. In particular, point mutations of UBQLN2 cause an X-linked, dominant form of amyotrophic lateral sclerosis (ALS), ALS with frontotemporal dementia (ALS/FTD), or FTD. Failed protein degradation is a hallmark of many neurodegenerative diseases, including ALS and FTD; however, it is not clear exactly how ALS/FTD-associated UBQLN2 mutations contribute to pathogenesis. Recent studies have revealed the complexity of UBQLN2 biology and allow deeper understanding as to how UBQLN2 dysfunction may contribute to neurodegenerative disease. UBQLN2 is necessary for mitochondrial protein degradation and for regulating mitochondrial turnover, both of which are essential for motor neurons and have been implicated in the pathogenesis of ALS. Stress granule (SG) formation and regulation are also affected by UBQLN2 mutations, and their dysregulation may contribute to the toxic protein aggregation and SG changes observed in neurodegenerative disease. Finally, there are compelling links connecting UBQLN2 dysfunction with changes to downstream neuronal morphology, function, and behavior. This review will detail the emerging consensus on how UBQLN2 protects against neurodegenerative disease and will provide insights into potential therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Colorado Boulder, Boulder, Colorado, 80309, U.S.A.
ORCID-Profile: Autumn M Matthews, Alexandra M Whiteley
Förderung
- NINDS NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Matthews, A. M., & Whiteley, A. M. (2025). UBQLN2 in neurodegenerative disease: mechanistic insights and emerging therapeutic potential. Biochemical Society Transactions. https://doi.org/10.1042/bst20253053
Vancouver
Matthews AM, Whiteley AM. UBQLN2 in neurodegenerative disease: mechanistic insights and emerging therapeutic potential. Biochemical Society Transactions. 2025. doi:10.1042/bst20253053
BibTeX
@article{Matthews2025,
author = {Matthews, Autumn M and Whiteley, Alexandra M},
title = {UBQLN2 in neurodegenerative disease: mechanistic insights and emerging therapeutic potential},
journal = {Biochemical Society Transactions},
year = {2025},
doi = {10.1042/bst20253053}
}
EUVIMED